Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Restoration of quality of life of patients with inflammatory bowel disease after one year with antiTNFα treatment.

Casellas F, Robles V, Borruel N, Torrejón A, Castells I, Navarro E, Guarner F.

J Crohns Colitis. 2012 Oct;6(9):881-6. doi: 10.1016/j.crohns.2012.01.019. Epub 2012 Feb 14.

PMID:
22398074
2.

Achievement of deep remission during scheduled maintenance therapy with TNFα-blocking agents in IBD.

Molander P, Sipponen T, Kemppainen H, Jussila A, Blomster T, Koskela R, Nissinen M, Rautiainen H, Kuisma J, Kolho KL, Färkkilä M.

J Crohns Colitis. 2013 Oct;7(9):730-5. doi: 10.1016/j.crohns.2012.10.018. Epub 2012 Nov 21.

PMID:
23182163
3.

Predictive value of early restoration of quality of life in Crohn's disease patients receiving antitumor necrosis factor agents.

Herrera-deGuise C, Casellas F, Robles V, Navarro E, Borruel N.

J Gastroenterol Hepatol. 2015 Feb;30(2):286-91. doi: 10.1111/jgh.12803.

PMID:
25302652
4.

Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease.

Casellas F, Barreiro de Acosta M, Iglesias M, Robles V, Nos P, Aguas M, Riestra S, de Francisco R, Papo M, Borruel N.

Eur J Gastroenterol Hepatol. 2012 Jul;24(7):762-9. doi: 10.1097/MEG.0b013e32835414b2.

PMID:
22517240
5.

Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.

Trinder MW, Lawrance IC.

J Gastroenterol Hepatol. 2009 Jul;24(7):1252-7. doi: 10.1111/j.1440-1746.2009.05786.x. Epub 2009 Feb 12.

PMID:
19220669
6.

Short-term response to adalimumab in childhood inflammatory bowel disease.

Noe JD, Pfefferkorn M.

Inflamm Bowel Dis. 2008 Dec;14(12):1683-7. doi: 10.1002/ibd.20534.

PMID:
18618629
7.

Health-related quality of life and disability in patients with ulcerative colitis and proctocolectomy with ileoanal pouch versus treatment with anti-TNF agents.

Meijs S, Gardenbroek TJ, Sprangers MA, Bemelman WA, Buskens CJ, D'Haens GR, Löwenberg M.

J Crohns Colitis. 2014 Jul;8(7):686-92. doi: 10.1016/j.crohns.2013.12.011. Epub 2014 Jan 11.

PMID:
24418659
8.

The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients.

Algaba A, Linares PM, Encarnación Fernández-Contreras M, Figuerola A, Calvet X, Guerra I, de Pousa I, Chaparro M, Gisbert JP, Bermejo F.

Inflamm Bowel Dis. 2014 Apr;20(4):695-702. doi: 10.1097/MIB.0000000000000004.

PMID:
24562175
9.

Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry.

Bokemeyer B, Hardt J, Hüppe D, Prenzler A, Conrad S, Düffelmeyer M, Hartmann P, Hoffstadt M, Klugmann T, Schmidt C, Weismüller J, Mittendorf T, Raspe H.

J Crohns Colitis. 2013 Jun;7(5):355-68. doi: 10.1016/j.crohns.2012.02.014. Epub 2012 Apr 12.

PMID:
22503168
10.

Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents.

Molander P, af Björkesten CG, Mustonen H, Haapamäki J, Vauhkonen M, Kolho KL, Färkkilä M, Sipponen T.

Inflamm Bowel Dis. 2012 Nov;18(11):2011-7. doi: 10.1002/ibd.22863. Epub 2012 Jan 4.

PMID:
22223566
11.

Analysis of TNF-antagonist switch over time and associated risk factors in the Swiss Inflammatory Bowel Disease Cohort.

Hiroz P, Vavricka SR, Fournier N, Safroneeva E, Pittet V, Rogler G, Schoepfer AM; Swiss Inflammatory Bowel Diseases Cohort Study Group..

Scand J Gastroenterol. 2014 Oct;49(10):1207-18. doi: 10.3109/00365521.2014.946082. Epub 2014 Aug 14.

PMID:
25120029
12.

Discontinuation of anti-tumor necrosis factor therapy in inflammatory bowel disease patients: a prospective observation.

Bortlik M, Duricova D, Machkova N, Hruba V, Lukas M, Mitrova K, Romanko I, Bina V, Malickova K, Kolar M, Lukas M.

Scand J Gastroenterol. 2016;51(2):196-202. doi: 10.3109/00365521.2015.1079924. Epub 2015 Sep 2.

PMID:
26329773
13.

Prospective assessment of the effect on quality of life of anti-tumour necrosis factor therapy for perineal Crohn's fistulas.

Ng SC, Plamondon S, Gupta A, Burling D, Kamm MA.

Aliment Pharmacol Ther. 2009 Oct;30(7):757-66. doi: 10.1111/j.1365-2036.2009.04088.x. Epub 2009 Jul 3.

14.

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.

Gisbert JP, Marín AC, McNicholl AG, Chaparro M.

Aliment Pharmacol Ther. 2015 Apr;41(7):613-23. doi: 10.1111/apt.13083. Epub 2015 Feb 4. Review.

15.

Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.

Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.

Am J Gastroenterol. 2009 May;104(5):1170-9. doi: 10.1038/ajg.2009.59. Epub 2009 Apr 7.

PMID:
19352339
16.

Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.

Molnár T, Farkas K, Nyári T, Szepes Z, Nagy F, Wittmann T.

J Gastrointestin Liver Dis. 2012 Sep;21(3):265-9.

17.

Long-term outcome of tumor necrosis factor alpha antagonist's treatment in pediatric Crohn's disease.

Assa A, Hartman C, Weiss B, Broide E, Rosenbach Y, Zevit N, Bujanover Y, Shamir R.

J Crohns Colitis. 2013 Jun;7(5):369-76. doi: 10.1016/j.crohns.2012.03.006. Epub 2012 Apr 5.

PMID:
22483567
18.

Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy.

Farkas K, Lakatos PL, Szűcs M, Pallagi-Kunstár É, Bálint A, Nagy F, Szepes Z, Vass N, Kiss LS, Wittmann T, Molnár T.

World J Gastroenterol. 2014 Mar 21;20(11):2995-3001. doi: 10.3748/wjg.v20.i11.2995.

19.

Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.

Colombel JF, Sandborn WJ, Ghosh S, Wolf DC, Panaccione R, Feagan B, Reinisch W, Robinson AM, Lazar A, Kron M, Huang B, Skup M, Thakkar RB.

Am J Gastroenterol. 2014 Nov;109(11):1771-80. doi: 10.1038/ajg.2014.242. Epub 2014 Aug 26.

20.

Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years.

Casellas F, Rodrigo L, Niño P, Pantiga C, Riestra S, Malagelada JR.

Inflamm Bowel Dis. 2007 Nov;13(11):1395-400.

PMID:
17567874

Supplemental Content

Support Center